Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.45 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17705192 | 0.90 | CCR5 (0.53) | CCR5ALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL16294701 | 0.89 | CCR5 (0.49) | CCR5ALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL7121592 | 0.83 | LRRK2 (0.49) | CCR5ALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL8166488 | 0.82 | CCR5 (0.58) | CCR5ALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL3915066 | 0.82 | CCR5 (0.60) | CCR5ALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL16294078 | 0.82 | PTGER1 (0.54) | CCR5ALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL16294077 | 0.82 | PTGER1 (0.54) | CCR5ALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL16294377 | 0.82 | PTGER1 (0.54) | CCR5ALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL1783156 | 0.81 | CCR5 (0.49) | CCR5ALDH1A1RAB9ALMNAUSP2 | |
| SCHEMBL8321821 | 0.81 | CCR5 (0.54) | CCR5ALDH1A1RAB9ALMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | CCR5 3177/4885ALDH1A1 2603/4885RAB9A 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.